According to Liu, his preferred option is faricimab, a fairly new agent that was FDA-approved for wet AMD in 2022. The drug ...

In this video, David A. Eichenbaum, MD, FASRS, discusses late-stage wet age-related macular degeneration assets presented at the American Academy of Ophthalmology meeting.Eichenbaum noted that ...

Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and improve vision outcomes for patients with wet AMD ARTEMIS ...

Topline clinical data from SOL-1 are now expected in Q4 2025 BEDFORD, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (OCUL) (NASDAQ: OCUL, “Ocular”, the “Company”), a ...

"Emerging wet AMD therapies including Fovista and abicipar pegol (Allergan/Molecular Partners) will need to be priced competitively to Eylea and Lucentis in order to garner favorable tier placement.

REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly ...

Clearside Biomedical, Inc. announced on March 20, 2025, that it presented findings on its lead clinical program, CLS-AX, a suprachoroidal injectable suspension of axitinib, at the 2025 Wet AMD & ...

Age-related macular degeneration (AMD) is a leading cause of vision loss among people aged 50 and older. While treatments for the wet form of AMD have shown promise, the dry form, which accounts for ...

Screening closing ahead of expectations, with full enrollment now anticipated in 4Q 2025 (previously 1Q 2026) ARTEMIS topline data readout accelerated to 1Q 2027 REDWOOD CITY, Calif., Sept. 22, 2025 ...

STOCKHOLM — Current treatments for age-related macular degeneration (AMD) have proven effective and safe. However, these lifelong therapies involve frequent ocular injections. "It can be ...

Age-related macular degeneration (AMD) remains a leading cause of vision loss globally, with significant advancements in treatment options for both dry and wet AMD. As highlighted by Huang and ...